PIPELINE WATCH: Five Approvals, Four Filings And Two Launches
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
You may also be interested in...
Among Europe’s flourishing niche of mid-sized pharmaceutical companies, Italy’s Recordati and Spain’s Almirall have snapped up smaller local companies during the past six to nine months, while Switzerland’s Actelion is concentrating on executing new product launches while considering M&A.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.